Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences Inc (NASDAQ: PLSE) pioneers bioelectric medicine through its proprietary Nano-Pulse Stimulation technology, offering investors and medical professionals a novel approach to non-thermal therapies. This dedicated news hub provides real-time updates on clinical advancements, regulatory developments, and strategic partnerships shaping the future of targeted cellular treatments.
Access verified information about PLSE's progress in immuno-oncology applications, dermatology research breakthroughs, and system commercialization efforts. Our curated feed includes earnings reports, FDA submissions, peer-reviewed study results, and executive commentary – all essential for evaluating the company's position in the electroceuticals market.
Key updates cover therapeutic trial milestones, intellectual property expansions, and collaborations with leading medical institutions. Bookmark this page to monitor how PLSE's drug-free energy modalities could transform treatment protocols for complex conditions while driving long-term value in the medical device sector.
Pulse Biosciences (Nasdaq: PLSE) announced inducement equity awards approved November 18, 2025 under its 2017 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The Compensation Committee granted options to three new employees to purchase an aggregate of 13,450 shares of common stock.
The options carry an exercise price of $13.58 per share (equal to the closing price on November 18, 2025) and vest on a time-based four-year schedule with 1/4 vesting annually, subject to continued employment and the award agreements.
Pulse Biosciences (Nasdaq: PLSE) will present at two investor conferences in New York in November–December 2025. Management is scheduled to speak at the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025 at 2:40 PM ET and at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 9:50 AM ET. Live and recorded webcasts will be available on the company investor website at http://investors.pulsebiosciences.com/.
Pulse Biosciences (Nasdaq: PLSE) reported Q3 2025 business updates and financial results for the quarter ended September 30, 2025. Key clinical milestones include FDA IDE approval and initial enrollment in the nPulse Cardiac Surgery System surgical AF study (NANOCLAMP AF), PRECISE-BTN study 40% enrolled for benign thyroid nodules, and submission/planned IDE start for the endocardial nPulse 360° catheter in Q1 2026. The company has treated over 200 patients across programs and generated $86 thousand revenue from limited market release.
Q3 GAAP costs and expenses were $20.5M (GAAP net loss $19.4M); non-GAAP loss was $13.5M. Cash and equivalents were $95.2M at September 30, 2025.
Pulse Biosciences (Nasdaq: PLSE) announced first U.S. patient enrollment in the NANOCLAMP AF Study on October 24, 2025, using the nPulse Cardiac Surgical System after receiving FDA IDE approval.
The single-arm, prospective multicenter study will evaluate safety and effectiveness of the nsPFA-driven nPulse Cardiac Clamp for atrial fibrillation during concomitant surgical procedures, with multiple U.S. and two international sites planned. The device holds FDA Breakthrough Device designation (July 2024) and is in the FDA TPLC Advisory Program.
Pulse Biosciences (Nasdaq: PLSE) will report third quarter 2025 business updates and financial results after market close on Wednesday, November 5, 2025.
Company management will host a conference call on November 5, 2025 at 1:30 PM PT / 4:30 PM ET. U.S. dial-in is 1-800-715-9871; international dial-in is 1-646-307-1963; use Conference ID 7706791. A live and recorded webcast will be available on the Pulse Biosciences investors website at http://investors.pulsebiosciences.com/.
Pulse Biosciences (Nasdaq: PLSE) announced that its Compensation Committee granted inducement equity awards to three new employees on October 14, 2025 under the company’s 2017 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards total up to 8,550 options to purchase common stock at an exercise price of $17.26 per share (equal to the October 14, 2025 closing price). Options vest over four years with 1/4 vesting annually and are subject to the plan and individual award agreements.
Pulse Biosciences (Nasdaq: PLSE) reported late-breaking first-in-human feasibility results for the nPulse™ Cardiac Surgical System presented at EACTS on October 10, 2025. The study has treated 44 patients, with electroanatomical mapping at ~3 months in 24 patients. Key outcomes in the initial cohort include 100% posterior box isolation (high-dose cohort), 94% pulmonary vein isolation per vein (63/67) at ~3 months, an average total ablation time of 50 seconds with ~13 applications, and no reports of esophageal or phrenic nerve injury or ablation-related severe/major adverse events. The company plans to initiate an IDE study later in 2025 to further validate the system for AF surgical ablation.
Pulse Biosciences (Nasdaq: PLSE) announced that early clinical data on its nPulse™ Cardiac Surgical System using nanosecond PFA (nsPFA) for atrial fibrillation will be presented at the 39th EACTS Annual Meeting in Copenhagen, October 8–11, 2025.
The company noted the FDA approval of an IDE study for the nPulse system and said clinicians will present safety and efficacy findings. Scheduled events include a presentation by Bart van Putte, MD on October 8 (Acquired Cardiac Techno-College, presentation at 10:40 AM, Hall A1) and a moderated e-poster on October 10 (First‑in‑Human nsPFA study, 12:30–1:00 PM, Moderated e‑Poster Station 2).
Pulse Biosciences (Nasdaq: PLSE), a company specializing in nPulse™ and Nanosecond Pulsed Field Ablation™ technology, has granted equity inducement awards to four new employees. The Compensation Committee approved stock options to purchase a total of 20,850 shares of common stock at an exercise price of $15.74 per share, matching the closing price on September 15, 2025.
The awards, granted outside the Company's 2017 Equity Incentive Plan but under the 2017 Inducement Equity Incentive Plan, will vest over four years with 25% vesting annually, contingent on continued employment.
[]Pulse Biosciences (Nasdaq: PLSE) announced the presentation of clinical data on benign thyroid nodule ablation using their nPulse™ Vybrance™ technology at the American Thyroid Association Annual Meeting in Scottsdale, AZ, from September 10-14th, 2025.
The company will showcase its novel Nanosecond Pulsed Field Ablation™ (nsPFA™) technology through multiple presentations, including a late-breaking oral abstract session by Dr. Ralph Tufano and a sponsored event featuring clinical experiences from leading physicians. The company has recently initiated patient treatments in their multicenter IRB study and aims to expand clinical evidence supporting their technology.
FAQ
What is the current stock price of Pulse Biosciences (PLSE)?
What is the market cap of Pulse Biosciences (PLSE)?
